ZLAB लाइव सिग्नल्स | Getagraph.com के साथ लाभ को अधिकतम करें

बेचें 104475 min ago

@ $19.52

जारी किया गया: 15 Feb 2024 @ 00:58

वापसी: -18.47%

पिछला सिग्नल: Feb 14 - 22:23

पिछला सिग्नल: खरीदें

वापसी: 2.55 %

Live Chart Being Loaded With Signals

Commentary (27 Apr 2024 @ 01:30):

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience primarily in Mainland China and Hong Kong...

Stats
आज की मात्रा	362 617
औसत मात्रा	639 958
बाजार मूल्य	1.57B
EPS	$0 ( 2024-02-27 )
अगली कमाई की तारीख	( $-0.930 ) 2024-05-08
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-4.55
ATR14	$0.0180 (0.11%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-03	Smiley Joshua L	Buy	7 145	American Depositary Shares
2024-04-04	Smiley Joshua L	Sell	1 988	American Depositary Shares
2024-04-03	Smiley Joshua L	Sell	7 145	Restricted Share Units
2024-04-03	Reinhart Harald	Buy	5 270	American Depositary Shares
2024-04-04	Reinhart Harald	Sell	2 105	American Depositary Shares

INSIDER POWER
72.37
Last 100 transactions
Buy: 2 027 943 \| Sell: 363 897

मात्रा सहसंबंध

लंबा: 0.01 (neutral)

छोटा: 0.57 (weak)

Signal:(43.755) Neutral

Zai Lab Ltd सहसंबंध

10 सबसे अधिक सकारात्मक सहसंबंध
MMAC	0.88
NETE	0.872
BOCH	0.84
TFSL	0.832
SHSP	0.828
SNFCA	0.824
LWAC	0.815
DOOO	0.809
CLGN	0.804

10 सबसे अधिक नकारात्मक सहसंबंध
RMRM	-0.867
SVAC	-0.866
PAIC	-0.846
SVOK	-0.828
GAINL	-0.815
TLGT	-0.81

क्या आप जानते हैं?

कोरलेशन एक सांख्यिकीय माप है जो दो चरों के बीच संबंध का वर्णन करता है। यह -1 से 1 तक का होता है, जहाँ -1 एक पूर्ण नकारात्मक कोरलेशन को दर्शाता है (जैसे ही एक चर बढ़ता है, दूसरा कम होता है), 1 एक पूर्ण सकारात्मक कोरलेशन को दर्शाता है (जैसे ही एक चर बढ़ता है, दूसरा भी बढ़ता है) और 0 कोई कोरलेशन नहीं होता है (चरों के बीच कोई संबंध नहीं है)।

कोरलेशन किसी भी दो चरों के बीच संबंध का विश्लेषण करने के लिए इस्तेमाल किया जा सकता है, न कि केवल स्टॉक में। यह वित्तीय, अर्थशास्त्र, मनोविज्ञान और अन्य क्षेत्रों में आमतौर पर उपयोग किया जाता है।

Zai Lab Ltd सहसंबंध - मुद्रा/वस्त्र

-0.23
( neutral )

-0.13
( neutral )

0.00
( neutral )

-0.31
( neutral )

0.04
( neutral )

Zai Lab Ltd वित्तीय

Annual	2023
राजस्व:	$266.72M
सकल लाभ:	$170.90M (64.08 %)
EPS:	$-3.46

FY	2023
राजस्व:	$266.72M
सकल लाभ:	$170.90M (64.08 %)
EPS:	$-3.46

FY	2022
राजस्व:	$215.04M
सकल लाभ:	$141.02M (65.58 %)
EPS:	$-5.03

FY	2021
राजस्व:	$144.31M
सकल लाभ:	$92.07M (63.80 %)
EPS:	$-9.07

Financial Reports:

No articles found.

Zai Lab Ltd

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience primarily in Mainland China and Hong Kong. The company's commercial products include Zejula, a once-daily small-molecule poly polymerase 1/2 inhibitor; Optune, a device that delivers tumor treating fields; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; and Qinlock to treat gastrointestinal stromal tumors. It also develops Odronextamab to treat follicular lymphoma, diffuse large B-cell lymphoma, and other B-celllymphomas; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Margetuximab for the treatment of breast and gastroesophageal cancers; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, pancreatic cancer, and other solid tumors; and Bemarituzumab to treat gastric and gastroesophageal junction cancer. In addition, the company develops CLN-081 for the treatment of patients with EGFR exon 20 insertion NSCLC; Elzovantinib, an orally bioavailable multi-targeted kinase inhibitor; Tebotelimab, a tetravalent IgG4 monoclonal antibody; Retifanlimab that inhibits interactions between PD-1 and its ligands; ZL-2309, an orally active, selective, and ATP-competitive cell division cycle 7 (CDC7) kinase inhibitor; ZL-1201, a humanized IgG4 monoclonal antibody; Efgartigimod to reduce disease-causing immunoglobulin G antibodies; ZL-1102, a human nanobody targeting interleukin- 17A; KarXT for the treatment of psychiatric and neurological conditions; ZL-2313, an investigational inhibitor of triple-mutant EGFR harboring; ZL-2314, an investigational inhibitor of double-mutant EGFR harboring; and Sulbactam/durlobactam for the treatment of serious infections caused by Acinetobacter. Zai Lab Limited was incorporated in 2013 and is headquartered in Shanghai, China.